Klinik for overvægtige

Klinikken for overvægtige.

Copenhagen Fertility Center har nu i 2 år arbejdet konsekvent med vægttab hos overvægtige kvinder i fertilitetsbehandling. Disse erfaringer har nu givet grundlag for en bredere behandling af både mænd og kvinder med overvægt, der har et ønske om at tabe sig.

Programmet på vores klinik for overvægtige består af 3 faser:

1)            Undersøgelse og blodprøver.

Her undersøger vi patienten og opretter en journal, ligesom vi screener for følgesygdomme til overvægten og eventuelle årsager. Med en henvisning fra din egen læge får du blodprøver og første konsultation gratis.

2)            Planlægning af forløb med en diætist og medicinsk vejleder.

Der laves en livstilsændringsplan, herunder diæt og motionsplan. Her bliver mulighederne for understøtende medicinsk behandling også gennemgået og patienten grundigt instrueret. Dette dækkes ikke af Sygesikringen.

3)            Opfølgnings forløb.

Konsultationer hver 14. dag, hvor vægt, medicin og livstil bliver gennemgået i en periode på 56 uger. Dette dækkes ikke af Sygesikringen.

 

Prisen uden medicin er 24.000 danske kroner man betaler i 6 rater a 4000 kroner med 2 måneders mellemrum.

 

Klinikken forsøger på denne måde at opnå samme resultater som på patienter, der tidligere blev tilbudt Gastric Bypass operationer. Erfaringerne fra disse operationer er, at der desværre er mange bivirkninger, hvorfor alt andet bør prøves først. Med denne klinik for overvægtige mener vi, at man kan nå meget langt uden operation.

Det specielle ved denne klinik for overvægtige er, at vi på samme tid kobler diætist, læge, livstilsekspert og individuel medicinsk behandling sammen. Vi har erfaring for, at et sådan forløb er meget effektivt. Udover vægtreduktionen opnås også forbedring i blodtryk og risikofaktorer for hjerte-kar sygdom reduceres.

Gastric Bypass operationer koster ofte op til 50.000 danske kroner, hvis du selv skal betale. Her er prisen betydeligt mindre, og der er et 1 år langt forløb planlagt, fra du starter i trygge hænder af klinikkens personale.

For patienter, der er medlem af sygeforsikringen Danmark, ydes der tilskud til Medicin. Er man gr. 5 medlem får man mellem 25 og 50% tilskud afh. om, man er berettiget til sygesikringstilskud til medicin eller ej. For patienter i gruppe 1 og 2 ydes mellem 50 og 100 % tilskud igen afh. , om man er berettiget til sygesikringstilskud eller ej. 

 

Referencer.

 

1.

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes =65 and <65 years of age: a pooled analysis from phase III studies.

Bode BW, Brett J, Falahati A, Pratley RE.

Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4.

PMID: 22055210 [PubMed - indexed for MEDLINE]

Related citations

 

2.

Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.

Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ.

PLoS One. 2012;7(12):e50117. doi: 10.1371/journal.pone.0050117. Epub 2012 Dec 6.

PMID: 23236362 [PubMed - indexed for MEDLINE] Free PMC Article

Related citations

 

3.

GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy.

Derosa G, Maffioli P.

Curr Clin Pharmacol. 2012 Aug;7(3):214-28. Review.

PMID: 22432846 [PubMed - indexed for MEDLINE]

Related citations

 

4.

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group.

Diabet Med. 2005 Aug;22(8):1016-23.

PMID: 16026367 [PubMed - indexed for MEDLINE]

Related citations

 

5.

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.

Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2012 Sep 14;11:107.

PMID: 22973968 [PubMed - indexed for MEDLINE] Free PMC Article

Related citations

 

6.

Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.

Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA, Taing S.

J Clin Endocrinol Metab. 2013 Sep;98(9):3599-607. doi: 10.1210/jc.2013-1040. Epub 2013 Jul 11.

PMID: 23846820 [PubMed - indexed for MEDLINE]

Related citations

 

7.

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder H, Nielsen L, Tu DT, Astrup A.

Diabetes Care. 2004 Aug;27(8):1915-21.

PMID: 15277417 [PubMed - indexed for MEDLINE]

Related citations

 

8.

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study.

Inoue K, Maeda N, Fujishima Y, Fukuda S, Nagao H, Yamaoka M, Hirata A, Nishizawa H, Funahashi T, Shimomura I.

Diabetol Metab Syndr. 2014 Sep 8;6(1):95. doi: 10.1186/1758-5996-6-95. eCollection 2014.

PMID: 25237400 [PubMed] Free PMC Article

Related citations

 

9.

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I.

Cardiovasc Diabetol. 2011 Dec 1;10:109. doi: 10.1186/1475-2840-10-109.

PMID: 22132774 [PubMed - indexed for MEDLINE] Free PMC Article

Related citations

 

10.

Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.

Jensterle M, Kocjan T, Kravos NA, Pfeifer M, Janez A.

Endocr Res. 2014 Oct 20:1-6. [Epub ahead of print]

PMID: 25330463 [PubMed - as supplied by publisher]

Related citations

 

11.

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.

Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A.

Eur J Endocrinol. 2014 Feb 7;170(3):451-9. doi: 10.1530/EJE-13-0797. Print 2014 Mar.

PMID: 24362411 [PubMed - indexed for MEDLINE] Free PMC Article

Related citations

 

12.

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL.

Clin Endocrinol (Oxf). 2014 Oct;81(4):523-8. doi: 10.1111/cen.12369. Epub 2013 Dec 12.

PMID: 24256515 [PubMed - in process]

Related citations

 

13.

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

Larsen PJ, Fledelius C, Knudsen LB, Tang-Christensen M.

Diabetes. 2001 Nov;50(11):2530-9.

PMID: 11679431 [PubMed - indexed for MEDLINE] Free Article

Related citations

 

14.

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.

Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, Yu DM.

Cardiovasc Diabetol. 2014 Feb 5;13:36. doi: 10.1186/1475-2840-13-36.

PMID: 24498905 [PubMed - indexed for MEDLINE] Free PMC Article

Related citations

 

15.

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR; NN2211-1310 International Study Group.

Diabetes Care. 2004 Jun;27(6):1335-42.

PMID: 15161785 [PubMed - indexed for MEDLINE]

Related citations

 

16.

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.

J Clin Endocrinol Metab. 2000 Aug;85(8):2767-74.

PMID: 10946879 [PubMed - indexed for MEDLINE]

Related citations

 

17.

Long-term effectiveness and safety of liraglutide in clinical practice.

Ponzani P.

Minerva Endocrinol. 2013 Mar;38(1):103-12.

PMID: 23435446 [PubMed - indexed for MEDLINE]

Related citations

 

18.

The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study.

Rasmussen CB, Lindenberg S.

Front Endocrinol (Lausanne). 2014 Aug 27;5:140. doi: 10.3389/fendo.2014.00140. eCollection 2014.

PMID: 25221543 [PubMed] Free PMC Article

Related citations

 

19.

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Nishida T, Kaku K.

Curr Med Res Opin. 2010 May;26(5):1013-22. doi: 10.1185/03007991003672551.

PMID: 20199137 [PubMed - indexed for MEDLINE]

Related citations

 

20.

Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.

Svendsen PF, Nilas L, Madsbad S, Holst JJ.

Metabolism. 2009 May;58(5):586-93. doi: 10.1016/j.metabol.2008.11.009.

PMID: 19375579 [PubMed - indexed for MEDLINE]

Related citations

 

21.

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.

Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, Aronne L; NN8022-1923 Investigators.

Int J Obes (Lond). 2013 Nov;37(11):1443-51. doi: 10.1038/ijo.2013.120. Epub 2013 Jul 1. Erratum in: Int J Obes (Lond). 2013 Nov;37(11):1514.

PMID: 23812094 [PubMed - indexed for MEDLINE]

Related citations

Bestil en gratis og helt uforpligtigende samtale med fertilitetslægen

KORT VENTETID! Udfyld formularen og vi vender tilbage snarest
Barnløshedsbehandling - udredning og forklaringer










Kort ventetid! Mandag til fredag 7:30 - 18:00 - Weekender 8:00 - 13:00
Vi har overenskomst med Sygesikringen. Copenhagen Fertility Center's priser og resultater.
  • The International Society for Mild Approaches in Assisted Reproduction (ISMAAR)